Menu
Search
|

Menu

Close
X

Alder Biopharmaceuticals Inc ALDR.OQ (NASDAQ Stock Exchange Global Market)

19.05 USD
-- (--)
As of 1:30 AM IST
chart
Previous Close 19.05
Open --
Volume --
3m Avg Volume 240,302
Today’s High --
Today’s Low --
52 Week High 19.55
52 Week Low 8.68
Shares Outstanding (mil) 67.71
Market Capitalization (mil) 863.35
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.17 Mean rating from 12 analysts

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
2
FY16
0
FY15
0
EPS (USD)
FY18
-1.733
FY17
-5.195
FY16
-3.222
FY15
-2.079
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.76
Price to Sales (TTM)
vs sector
1,264.05
5.73
Price to Book (MRQ)
vs sector
2.93
5.47
Price to Cash Flow (TTM)
vs sector
--
23.29
Total Debt to Equity (MRQ)
vs sector
0.00
16.84
LT Debt to Equity (MRQ)
vs sector
0.00
12.51
Return on Investment (TTM)
vs sector
-76.39
14.61
Return on Equity (TTM)
vs sector
-76.45
16.34

EXECUTIVE LEADERSHIP

Robert Azelby
President, Chief Executive Officer, Since 2018
Salary: --
Bonus: --
Erin Lavelle
Chief Operating Officer, Since 2018
Salary: --
Bonus: --
Larry Benedict
Executive Vice President, Principal Accounting Officer, Since 2016
Salary: $278,634.00
Bonus: --
Elisabeth Sandoval
Chief Commercial Officer and Executive Vice President of Corporate Strategy, Since 2018
Salary: $129,590.00
Bonus: --
James Bucher
Senior Vice President, General Counsel, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

11804 N Creek Pkwy S
BOTHELL   WA   98011-8801

Phone: +1425.2052900

Alder BioPharmaceuticals, Inc., is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms. Alder's lead pivotal-stage product candidate, eptinezumab, is being evaluated for migraine prevention. Eptinezumab is a monoclonal antibody that inhibits calcitonin gene-related peptide (CGRP), a protein that is active in mediating the initiation of migraine. Alder is additionally evaluating ALD1910, a preclinical product candidate also in development as a migraine prevention therapy. ALD1910 is a monoclonal antibody that inhibits pituitary adenylate cyclase-activating polypeptide-38 (PACAP-38), another protein that is active in mediating the initiation of migraine. Clazakizumab, Alder's third program, is a monoclonal antibody candidate that inhibits interleukin-6 and is licensed to Vitaeris, Inc.

SPONSORED STORIES